Abstract
BACKGROUND: Diabetes mellitus (DM) is a fast-growing metabolic disorder, which affect millions around the world mostly people from developing nations. The rise of diabetes is further set to rise more in the coming years in all inhabited continents of the world. DM mainly attributed for food and lifestyle changes, less or no physical activity, obese, overweight, and major socioeconomic changes. In recent years, herbal medicine is incredibly growing because many natural products exhibit less or no side effects. It is well-established that nature-derived products protect β-cells and decrease blood glucose.
AIM: We aimed to explain anti-diabetic attributes, traditional uses, and potential chemical constituents of desert plant retama.
RESULTS: Numerous previous studies support the use of plant derived bioactive substances for human and animal disease therapy and reinforce their importance as a potential source of novel drug candidates. In this line a flowering bush, belong to the genus “Retama” (Fabaceae) are in use of conventional remedy in the Mediterranean basin for various diseases including DM. This potential plant genus has a great medical and socioeconomic importance and provides crucial evidence for its anti-diabetic therapeutic potential. The present review collected various documented information using the following searching engines such as PubMed, Science direct, and Google scholar. We limit our search only to English written documents for the last few decades until date. For data mining, the following MeSH words used in the databases: Retama, diabetes, phytoconstituents, pharmacological potential, anti-diabetic, insulin, in vivo, and in vitro.
CONCLUSION: The outcome of this review may set new prospects for the DM patients, along with other standard medication and provide an overall insight to the well-being at the regional and global level.
Publisher
Scientific Foundation SPIROSKI
Reference111 articles.
1. IDF. IDF Diabetes Atlas. 10th ed. Belgium: IDF; 2022. Available from: https://diabetesatlas.org [Last accessed on 2021 Nov 08].
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321.
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843 PMid31518657
4. Florencia A, Alex B, Ho CN, Gisela D, Sheree D, Trisha D, et al. IDF Diabetes Atlas. 6th ed. Basel, Switzerland: International Diabetes Federation; 2013.
5. Orazumbekova B, Issanov A, Atageldiyeva K, Berkinbayev S, Junusbekova G, Danyarova L, et al. Prevalence of impaired fasting glucose and Type 2 diabetes in kazakhstan: Findings from large study. Front. Public Health. 2022;10:810153. https://doi.org/10.3389/fpubh.2022.810153 PMid35284393